Centauritherapeutics
2 known investors
Centauri Therapeutics is an immunotherapy company developing treatments for infectious diseases and oncology using its proprietary Alphamer technology, which redirects naturally existing antibodies against life-threatening diseases. Its pipeline includes clinical candidates targeting bacterial infections, including Gram-negative infections.
Investors · 2
Companies House · registry record
View on Companies House ↗- Registered name
- CENTAURI THERAPEUTICS LIMITED
- Company number
- 08879741
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 6 Feb 2014
- Registered office
- First Floor, 5 Fleet Place, London, EC4M 7RD
- Nature of business (SIC)
- 96090 — Other service activities n.e.c.
- Previous names
- ALTERMUNE LIMITED (2015–2015)ALTERMET LIMITED (2014–2015)
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 6 Feb 2026 · next due 20 Feb 2027
Current officers · 7
- Antonio Felici — director, appointed 9 Jun 2025
- Camilla Petrycer Hansen — director, appointed 26 Jan 2022
- Sebastian Tobias Kreuz — director, appointed 31 Jan 2025
- Stuart John Lawson — director, appointed 6 Feb 2014
- David Roblin — director, appointed 1 May 2022
- Henni-Karoliina Ropponen — director, appointed 7 Jan 2026
- Jennifer Robin Schneider — director, appointed 1 Sept 2021
Source: Companies House public register · retrieved 7 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.